• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    The Bull Case For MannKind (MNKD) Could Change Following FDA Approval Of At-Home Furoscix ReadyFlow Autoinjector – Learn Why

    Simply Wall St·07/25/2026 03:35:22
    Listen to the news
    • MannKind Corporation recently announced that the U.S. FDA approved Furoscix ReadyFlow, an at-home autoinjector delivering IV-equivalent furosemide for treating edema in adults with heart failure or chronic kidney disease, with dosing completed in under 10 seconds.
    • This approval opens a new at-home care option in a very costly disease area and may expand MannKind’s reach beyond hospital-based treatment.
    • We’ll now explore how FDA approval of this rapid at-home Furoscix ReadyFlow autoinjector could influence MannKind’s broader investment narrative.

    AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

    MannKind Investment Narrative Recap

    To own MannKind, you need to believe its inhaled and home-based therapies can grow beyond a concentrated portfolio while the company manages ongoing losses and financing needs. FDA approval of Furoscix ReadyFlow adds a new at-home asset in a costly disease area, but it does not immediately change that the key near term catalyst is Afrezza’s pediatric and broader adoption, while the biggest risk remains execution and uptake across a still narrow set of commercial products.

    The recent private placement to raise about US$49,975,872 sits alongside the Furoscix ReadyFlow approval as an important piece of the near term story. Fresh capital can help support the launch of ReadyFlow and ongoing R&D, but it also underlines the risk that MannKind may need continued external funding while it is unprofitable and working to expand revenue beyond Afrezza and Tyvaso DPI royalties.

    Yet investors should also weigh how this reliance on new capital could affect shareholders over time if...

    Read the full narrative on MannKind (it's free!)

    MannKind's narrative projects $554.4 million revenue and $85.4 million earnings by 2029.

    Uncover how MannKind's forecasts yield a $7.59 fair value, a 84% upside to its current price.

    Exploring Other Perspectives

    MNKD 1-Year Stock Price Chart
    MNKD 1-Year Stock Price Chart

    The most optimistic analysts already expected revenue of about US$649.6 million and earnings near US$168.9 million by 2029, so Furoscix ReadyFlow could either reinforce that bullish view or highlight how uncertain those assumptions are, depending on how you see the risks around payer pressure and adoption of inhaled and at-home therapies.

    Explore 3 other fair value estimates on MannKind - why the stock might be worth over 2x more than the current price!

    Decide For Yourself

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    Searching For A Fresh Perspective?

    Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.